Levodopa in the treatment of Parkinson’s disease
Author:
- 1 January 2006
- book chapter
- Published by Springer Nature
- No. 71,p. 1-15
Abstract
Levodopa is the most efficacious drug to treat the symptoms of Parkinson’s disease (PD) and is widely considered the “gold standard” by which to compare other therapies, including surgical therapy. Response to levodopa is one of the criteria for the clinical diagnosis of PD. A major limiting factor in levodopa therapy is the development of motor complications, namely dyskinesias and motor fluctuations. The ELLDOPA study was designed to determine if levodopa affected the progression of PD. This double-blind randomized study showed that the subjects treated with levodopa for 40 weeks had less severe parkinsonism than the placebo treated subjects even after a 2-week washout of medications, with the highest dose group showing the greatest benefit. Thus, levodopa may actually have neuroprotective value, but the result was not conclusive of slowing disease progression, because the same result could have arisen from a very long-lasting symptomatic benefit of levodopa.Keywords
This publication has 77 references indexed in Scilit:
- Prevalence and Characteristics of Dementia in Parkinson DiseaseArchives of Neurology, 2003
- Implications of the 5-year CR FIRST trialNeurology, 1998
- LevodopaNeurology, 1998
- Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s DiseaseEuropean Neurology, 1997
- “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's diseaseNeurology, 1991
- The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopaNeurology, 1991
- Does levodopa aggravate Parkinson's disease?Neurology, 1988
- Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlationsJournal of the Neurological Sciences, 1973
- Was leistet L-Dopa bei der Behandlung der Parkinson-Akinese?*DMW - Deutsche Medizinische Wochenschrift, 1967
- 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine AntagonistsNature, 1957